Vaccine for early Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests a new investigational vaccine called TRB-001 for people with early Parkinson's disease. It looks at whether the vaccine is safe and whether it can help the immune system fight the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 40 to 75 years old
- Diagnosed with Parkinson's disease within the last 4 years
- Mild Parkinson's symptoms (score of 2 or less on the Hoehn and Yahr scale)
- Brain MRI results consistent with Parkinson's disease
- If you take Parkinson's medications, your doses must be stable for at least 3 months before starting
- No history of autoimmune disease, active infections like hepatitis B/C or HIV, or significant immune problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This trial tests a new oral medication, VG081821AC, in people with early to mid-stage Parkinson's disease. The goal is to see if it can improve movement symptoms and slow the progression of the condition, and it may offer a new treatment option for those not yet on levodopa.
This trial tests a new treatment called NouvNeu001 for people with Parkinson's disease. It aims to see if it's safe, feasible, and effective in improving motor symptoms.
This study tests an experimental vaccine called TRB-001 in people with Parkinson's disease who have already received a previous immunotherapy targeting alpha-synuclein. The goal is to see if the vaccine is safe and how it affects the immune system and the disease.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new gene therapy called BBM-P002 for Parkinson's disease. It aims to see if the treatment is safe and tolerable, and may help people with moderate to advanced Parkinson's who have had the condition for at least 5 years.
Hear when a new Parkinson Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.